UK patients asking about Wegovy in 2026 increasingly want to know how the two formats actually compare in real life. The pill and the injectable both contain semaglutide as the active ingredient, but the practical experience of taking them — daily routine, food rules, side-effect pattern, expected weight loss — looks quite different. This article walks through where the two formats line up, where they diverge, and how a UK clinician approaches the choice at consultation.

Same active ingredient, different delivery

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone released after eating, slowing stomach emptying and reducing appetite signals to the brain. Whether the molecule arrives via a weekly injection or a daily tablet, the underlying mechanism is the same.

The two formats differ in how the molecule reaches the bloodstream. The injectable Wegovy pen delivers semaglutide subcutaneously, so the drug crosses into circulation reliably. The oral Wegovy tablet pairs semaglutide with an absorption enhancer (SNAC) that lets a small percentage of each dose cross the stomach lining — provided the patient takes it correctly, which is the part most people underestimate.

Dosing — daily routine vs weekly injection

The two formats run on very different rhythms:

  • Injectable Wegovy. One dose per week, given under the skin of the abdomen, thigh or upper arm. Doses titrate over 16+ weeks from 0.25 mg up to a maintenance dose of 2.4 mg weekly. The injection day can be chosen and kept consistent week to week.
  • Oral Wegovy. One tablet per day, every day, taken on an empty stomach first thing in the morning with no more than 120 ml of plain water. The patient must then wait at least 30 minutes before eating, drinking anything else, or taking other oral medication. Doses titrate from 3 mg up over several weeks to a higher maintenance strength.

The food-timing rule for the oral form isn't optional. Eating, drinking coffee, or even taking other tablets inside the 30-minute window substantially reduces how much of the dose actually enters the bloodstream. This is one of the most important practical differences between the two formats — the injection has no equivalent routine constraint.

Trial-level efficacy — what the head-to-head signals suggest

The most-quoted trial number for the injectable Wegovy pen is the STEP-1 result — mean weight loss in the region of around 15% at 68 weeks on the 2.4 mg weekly maintenance dose, alongside lifestyle support. For oral semaglutide at its highest studied dose, the OASIS-1 trial reported mean weight loss that was meaningful and well above placebo, but generally lower than the headline figure for the injectable.

Three caveats are worth keeping in mind:

  • Population averages, not personal predictions. Some patients lose more than the mean; some lose less. The trial number describes a distribution, not a guarantee for any individual.
  • Different studies, different populations. Comparing across trials should be done carefully. Inclusion criteria, support packages and follow-up windows aren't identical.
  • Dose matters. A patient who can't tolerate the highest dose of either format will see less weight loss than the trial headline. Real-world tolerability matters more than peak-dose efficacy on paper.

For more on how the broader GLP-1 family compares, see our piece on which weight-loss injection works best.

Side-effect comparison — what's similar, what's different

Because both formats deliver the same active ingredient via the same receptor, the broad side-effect profile is similar. The most common issues are gastrointestinal: nausea, constipation, reflux, occasional diarrhoea, and a fatigue or "off" feeling early in titration. Most are dose-related and tend to settle as the body adapts.

Where the two formats can feel different in practice:

  • Daily exposure (oral) vs weekly peak (injection). The daily tablet produces a more steady-state exposure. The weekly injection has higher post-injection peaks and a slow trough by the end of the week. Some patients notice the rhythm; others don't.
  • Onset of side effects. With the injectable, GI symptoms often cluster in the day or two after each weekly dose. With the daily tablet, symptoms can be more constant but milder.
  • Recovery from a bad dose. If a tablet causes a difficult day, only that day's dose is in the system. With the weekly pen, a tough injection can shadow several days.

Serious adverse events — pancreatitis, gallbladder events, severe dehydration — can occur with either format and need urgent clinical review.

Practical considerations — lifestyle, travel, needle aversion

Side by side, the practical experience of each format differs:

  • Food timing. The oral form imposes a strict morning routine. The injectable has none.
  • Travel. The injectable needs cold-chain or careful temperature management. The oral travels more simply but needs the fasting window honoured in different time zones.
  • Needle aversion. Patients who genuinely cannot face a weekly injection sometimes prefer the daily tablet, accepting the trade-off in trial-level weight loss.
  • Polypharmacy. The 30-minute fasting window for the oral form applies to other oral medications too. Patients on multiple morning medications may need their schedule reworked, or the injection may be a cleaner fit.
  • Memory and routine. Some patients prefer a single weekly act; others find a daily ritual easier to remember.

Who tends to be steered toward each format in UK practice

There's no rigid rule, but consultations tend to favour the injection when trial-level weight loss is a high priority, when the patient is comfortable with self-injection, and when morning routines are unpredictable. The oral tablet tends to come into focus when needle aversion is significant, when the patient has a steady early morning, and when the lower mean weight loss is an acceptable trade-off for a daily rather than weekly cadence.

Mounjaro (tirzepatide) is sometimes part of the conversation too. It's a different molecule — a dual GIP/GLP-1 receptor agonist — taken as a weekly injection, and only available in injectable form. Some patients ultimately move from a semaglutide format to tirzepatide or vice versa; that is also a clinician-led decision. Our guide on how a weight-loss injection works covers the underlying mechanism in more depth, and can I stay on a low dose of Wegovy explores the maintenance question that follows the format choice.

NICE pathway equivalence

From a NICE pathway point of view, oral and injectable semaglutide sit within the same overarching weight-management framework: medicine alongside diet, physical activity and behavioural support, with regular review. NHS access for either format is through specialist tier-3 or tier-4 services and is rationed against NICE criteria. Most UK patients exploring semaglutide for weight management privately do so through a UK-registered pharmacy after a structured consultation.

Working with your Farmeci clinician

The pill-versus-injection decision isn't a ranking exercise — it's a fit exercise. A UK-registered clinician will review your medical history, current medications, BMI, lifestyle, morning routine and tolerance for either delivery format, then talk through honest trade-offs. There's no single "right" Wegovy format that suits everyone, and your clinician will advise based on your individual circumstances. Bring honest information about how you live: that's what makes the consultation useful.